AKT1 and prostate carcinoma: In SIRT3 overexpressed prostate cancer cells we transfected a constitutively active, myristoylated form of Akt (Myr-Akt), or applied LY294002, a selective inhibitor of the PI3K/Akt pathway to inhibit p-Akt Ser473 signals [34] (Figure S7).